



ASX ANNOUNCEMENT

21 November 2023

Reset Mind Sciences Investor Webinar



Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to invite investors to attend an inaugural webinar from subsidiary Reset Mind Sciences Ltd (“Reset”), providing an overview of the business, its demerger activities and plans to raise capital. The webinar will be presented by Reset Chief Operating Officer Dr Leon Warne and will be followed by a question-and-answer session. Details of the webinar are as follows:

Date: Tuesday, 21st November 2023

Time: 10:00am AWST / 1:00pm AEDT.

Format: Zoom Webinar. To register your attendance for the webinar, please click the link below:

https://us02web.zoom.us/webinar/register/WN_hIxRkzI4TuGWPJz5gERWRw

The Company further advises that details of the Reset Priority and Public Offers can be found in the Prospectus lodged with ASIC on 9 November 2023.

Both the Priority and Public Offers close on 1 December 2023. Further information on the Offers can be found at www.resetmind.com.au and <https://investlittlegreenpharma.com/>.

Before deciding to invest in Reset, investors should read the Prospectus in its entirety and consider the risk factors set out in the Prospectus.

**ENDS
BY ORDER OF THE BOARD**



Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, with its Danish facility being one of the largest GMP medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp